Online Library
Two-year follow-up of 23 implantoplasty cases applying a novel “platform switch” technique
EAO Online Library. Galárraga-Vinueza M. Oct 9, 2018; 232714; P-SU-21
María Elisa Galárraga-Vinueza
María Elisa Galárraga-Vinueza
Login now to access Regular content available to all registered users.
Discussion Forum (0)
Rate & Comment (0)
Several non-surgical and surgical therapies have been proposed to counteract the controversial peri-implantitis (PI) and stop the progression of peri-implant bone loss+ however, until now none of them has been selected as a “gold standard” treatment for PI. **The aim of this retrospective study is to evaluate the success rate of 23 PI cases treated by a combined surgical resective implantoplasty therapy applying a novel “platform switch” technique to not only smooth and decontaminate but to provide a newly formed biologic space for peri-implant tissues. Twenty-three patients (n-23) fulfilled the 2-year follow-up evaluation following access flap surgery, removal of granulation tissue, implantoplasty and citric acid (20%) decontamination of the exposed supracrestally threads in a bottle like format replicating the “platform switch” concept (fig 1). The implants were evaluated through clinical and radiographic analysis before(T0), after the surgical treatment(T1), and after 2-years follow-up(T2) (figure2). Implantoplasty success rate was determined by the following parameters- absence of pain, mobility, suppuration, implant fracture, and no-progressive bone loss. **At 24 months, novel “platform switch” implantoplasty treated PI cases showed a success rate of 91.3% meaning that 21 cases were resolved showing no pain, mobility, suppuration, fracture, and non-observed progressive bone loss. Moreover, the radiographic analysis showed that 3 or (13%) treated implants had a mesial bone gain of (1.6 ±0.1mm) which could be considered as a possible re-osseointegration. Only one implant showed progressive bone loss (4.3%) of 1.5mm (mesially) after the 24-month follow up+ however, the implant did not show any other clinical signs or symptoms revealing a PI diagnosis. One implant was lost after one year of treatment due to mobility, presenting a failure rate of 4.3%. Bleeding on probing (BOP) reduced from a baseline of (86.9 ±2%) to (13 ±3%) after the 24-month follow-up. **Considering there is no “gold standard” treatment for PI, the relevant 2-year follow-up success rate of combined surgical resective and novel “platform switch” implantoplasty therapy shows that this modified technique is promising since it counteracted progressive bone loss and eliminated PI signs and symptoms in more than 90% of the cases. Importantly, this therapy showed bone gain in smoothened surfaces in 13% of the cases, which is the current desired goal of peri-implantitis treatment.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings